Your browser doesn't support javascript.
loading
Integrated analysis of recombinant BPV-1 L1 protein for the production of a bovine papillomavirus VLP vaccine
Módolo, Diego Grando; Araldi, Rodrigo Pinheiro; Mazzuchelli-de-Souza, Jacqueline; Pereira, Alexandre; Pimenta, Daniel Carvalho; Zanphorlin, Leticia Maria; Beçak, Willy; Menossi, Marcelo; Stocco, Rita de Cassia; Carvalho, Rodrigo Franco de.
Afiliación
  • Módolo, Diego Grando; Instituto Butantan. Laboratório de Genética.
  • Araldi, Rodrigo Pinheiro; Instituto Butantan. Laboratório de Genética.
  • Mazzuchelli-de-Souza, Jacqueline; Instituto Butantan. Laboratório de Genética.
  • Pereira, Alexandre; Instituto Butantan. Laboratório de Genética.
  • Pimenta, Daniel Carvalho; Instituto Butantan. Laboratório de Bioquímica e Biofísica.
  • Zanphorlin, Leticia Maria; Instituto Butantan. Laboratório de Genética.
  • Beçak, Willy; Instituto Butantan. Laboratório de Genética.
  • Menossi, Marcelo; Instituto Butantan. Laboratório de Genética.
Vaccine ; 35(12): 1590-1593, 2017.
Article en En | SES-SP, SESSP-IBPROD, SES-SP | ID: but-ib15393
Biblioteca responsable: BR78.1
Ubicación: BR78.1
ABSTRACT
Bovine papillomatosis is an infectious disease that is caused by bovine papillomavirus (BPV), which results in important economic losses. However, no BPV vaccines or effective treatment methods are commercially available to date. Moreover, the absence of papillomavirus replication in vitro makes the use of recombinant protein a promising candidate for vaccine formulations. Hence, we developed an integrated study on the L1 capsid protein of BPV-1, obtained from a bacterial expression system, regarding its purification, biosafety, thermostability and immunogenicity. The results indicated an absence of genotoxicity of the purified recombinant L1 protein, beta-sheet prevalence of secondary structure folding, protein stability under high temperatures as well as the presence of capsomeres and VLPs. In addition, preliminary experimental vaccination of calves showed the production of specific antibodies against BPV-1 L1.
Texto completo: 1 Colección: 06-national / BR Base de datos: SES-SP / SESSP-IBPROD Idioma: En Revista: Vaccine Año: 2017 Tipo del documento: Article
Texto completo: 1 Colección: 06-national / BR Base de datos: SES-SP / SESSP-IBPROD Idioma: En Revista: Vaccine Año: 2017 Tipo del documento: Article